Moleculin Biotech Inc. (MBRX)
MBRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1659617/000143774926008841/0001437749-26-008841-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | MBRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2016 |
| SEC CIK | 0001659617 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$33.6M |
| Operating income | -$25.1M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $8.9M |
| Total assets | $22.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt regarding the Company's ability to continue as a going concern." | 10-Q 2026-11-13 |
| Cash and burn | $7.3M cash; operating cash flow -$6.3M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,061,533 (2026-11-06); 50,910,476 a year earlier; 29,810,443 three years earlier. 1y figure adjusted for splits (1-for-500 overall); 3y figure adjusted for splits (1-for-7500 overall). | Cover page 2026-11-06 |
| Reverse splits, 3 years | 3; latest 1-for-20 on 2026-10-20 | Source 2026-10-20 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-08-21 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-09-18 |
| Auditor | Grant Thornton LLP, Ft. Lauderdale, Florida, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $0 | -$7.6M | -$6.7M | $7.3M | No debt tags | $0 | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $0 | -$12.8M | -$6.1M | $10.3M | No debt tags | $0 | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $0 | $15.6M | -$5.4M | $8.9M | No debt tags | $0 | 10-K 2026-03-18 |
| Q3 2025 2025-09-30 | $0 | -$25.4M | -$7.2M | $6.7M | No debt tags | $0 | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | $0 | -$17.8M | -$5.6M | $7.6M | No debt tags | $0 | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $0 | -$5.9M | -$4.6M | $7.7M | No debt tags | $0 | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $0 | -$6.6M | -$5.1M | $4.3M | No debt tags | $0 | 10-K 2026-03-18 |
| Q3 2024 2024-09-30 | $0 | -$7.0M | -$6.1M | $9.4M | No debt tags | $0 | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2026-08-21 |
| Latest annual report FORM 10-K/A | 10-K/A | 2026-04-14 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-13 |
| Latest current report FORM 8-K | 8-K | 2026-11-16 |
| Latest proxy FORM DEFA14A | DEFA14A | 2026-08-24 |
Source: SEC EDGAR submissions feed, 846 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.5% |
| 1 month | -9.5% |
| 3 months | -31.1% |
| Year to date | +137.8% |
| 1 year | -30.7% |
| From 52-week high | -91.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| UPC | Universe Pharmaceuticals Inc. | $1.48 | -1.99% | $7.4M |
| GTBP | GT Biopharma Inc. | $3.54 | -1.81% | $7.3M |
| CURX | Curanex Pharmaceuticals Inc | $4.63 | -0.11% | $7.3M |
| IMRN | Immuron Limited | $0.8996 | +2.23% | $7.3M |
| LGVN | Longeveron Inc. | $2.14 | -14.06% | $7.2M |
| ENSC | Ensysce Biosciences Inc. | $0.4095 | -2.13% | $8.0M |
| RKTO | Rocket One Inc. | $0.3210 | +0.03% | $8.0M |
| MTVA | MetaVia Inc. | $1.21 | -7.31% | $8.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier